Fluphenazine side effects: EPS and the first-generation profile

Fluphenazine, sold for decades under brand names like Prolixin and Modecate, is one of the older high-potency first-generation antipsychotics. It is still widely used worldwide — partly because it works, partly because it is inexpensive, and partly because its long-acting injectable form (fluphenazine decanoate) was one of the first depot antipsychotics ever developed. The trade-off is a side effect profile shaped almost entirely by its strong dopamine D2 receptor blockade, which means movement effects sit at the top of the list.

Why the side effects look the way they do

Fluphenazine has very tight binding to D2 receptors and relatively little serotonin receptor activity. High-potency D2 blockade in the basal ganglia is what produces movement side effects. Compared with low-potency first-generation drugs like chlorpromazine, fluphenazine causes less sedation, less weight gain, and less anticholinergic burden — but more EPS, more akathisia, and more long-term motor risk. The StatPearls fluphenazine review summarises the receptor profile and clinical implications.

Extrapyramidal symptoms (EPS)

EPS is an umbrella term for a cluster of drug-induced movement problems. With fluphenazine, several can appear:

Acute dystonia

Sudden involuntary muscle spasms — most often of the neck (torticollis), eyes (oculogyric crisis), tongue, or jaw. These can appear within hours to days of starting fluphenazine or after a dose increase, and they are frightening but treatable. Intramuscular benztropine or diphenhydramine usually resolves a dystonic reaction within minutes. Younger men are at the highest risk.

Drug-induced parkinsonism

Tremor, muscular rigidity, slowed movement (bradykinesia), shuffling gait, and reduced facial expression — closely resembling Parkinson's disease. Onset is usually over days to weeks. See our overview of EPS for management strategies, which often include dose reduction, switching agents, or adding an anticholinergic such as benztropine or trihexyphenidyl.

Akathisia

An inner sense of restlessness — usually felt in the legs — that drives constant movement, pacing, and an inability to sit still. Patients often describe it as the most distressing side effect of antipsychotic treatment, and it is associated with treatment dropout and even suicidality. Strategies include lowering the dose, adding propranolol, or adding a low-dose benzodiazepine. See our akathisia management guide.

Tardive dyskinesia (TD)

Slow-developing, often irreversible involuntary movements (lip smacking, tongue thrusting, finger movements). Risk increases with cumulative exposure, age, and being female. First-generation antipsychotics like fluphenazine carry a higher TD risk than most second-generation drugs — roughly 5% per year of exposure in adults. The FDA has approved valbenazine and deutetrabenazine for treatment. See our TD overview.

Hyperprolactinemia

D2 blockade in the pituitary stalk lifts prolactin, often substantially. Symptoms include menstrual changes, breast tenderness, milk production (galactorrhoea) in either sex, and reduced libido or erectile dysfunction. Long-term elevation may contribute to bone density loss. Many clinicians get a baseline prolactin and recheck if symptoms appear. See our hyperprolactinemia article.

Sedation, anticholinergic effects, and metabolic profile

Compared with low-potency typicals and most second-generation drugs, fluphenazine is comparatively kind to the metabolism. Weight gain is usually modest. Anticholinergic side effects (dry mouth, constipation, blurred vision, urinary hesitancy) are present but milder than with chlorpromazine or thioridazine. Sedation is typically less prominent than with quetiapine or olanzapine. For people who cannot tolerate metabolic side effects of newer drugs, this is part of why fluphenazine still has a niche.

Cardiovascular effects

Fluphenazine can prolong the QTc interval on ECG, although less than thioridazine or droperidol. Risk rises in the presence of other QT-prolonging drugs, electrolyte abnormalities, or pre-existing heart disease. See our QT prolongation article. Orthostatic hypotension is possible but milder than with low-potency agents.

Neuroleptic malignant syndrome (NMS)

The decanoate (long-acting injection)

Fluphenazine decanoate is given intramuscularly every 2 to 4 weeks. It removes the day-to-day question of adherence and produces steadier plasma levels. The trade-off is that if a side effect occurs, the medication cannot simply be stopped — it remains in the body for weeks. Lowest effective doses are emphasised. See our broader discussion of LAIs vs oral antipsychotics.

Practical questions to ask your prescriber

• What is the lowest dose likely to control my symptoms?
• Will we monitor for movement side effects on a schedule (such as the AIMS exam)?
• What should I do if I develop muscle stiffness, tremor, or restlessness?
• Are there reasons to consider a second-generation alternative now or later?
• If I switch to the long-acting form, what is the plan for the first months?

The big picture

Fluphenazine is a serious, effective medication that rewards careful management. People who do well on it often do so because they have a clinician who is attentive to early movement side effects, willing to lower the dose to the smallest effective amount, and proactive about screening for tardive dyskinesia over years. For people whose primary problem is positive symptoms and who tolerate the receptor profile, it can be a stable, affordable foundation for recovery. For others, the side effect cost outweighs the benefit and a different agent is appropriate. That decision belongs to you and your prescriber.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.